A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Receptor activator of NF-kB ligand stimulates NF-kB–dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid in bone metastatic solid tumors suggested significant overall survival (OS) advantage fo...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of thoracic oncology 2020-10, Vol.15 (10), p.1647-1656
Hauptverfasser:	Peters, Solange, Danson, Sarah, Hasan, Baktiar, Dafni, Urania, Reinmuth, Niels, Majem, Margarita, Tournoy, Kurt G., Mark, Michael T., Pless, Miklos, Cobo, Manuel, Rodriguez-Abreu, Delvys, Falchero, Lionel, Moran, Teresa, Ortega Granados, Ana Laura, Monnet, Isabelle, Mohorcic, Katja, Sureda, Bartomeu Massutí, Betticher, Daniel, Demedts, Ingel, Macias, Jose Antionio, Cuffe, Sinead, Luciani, Andrea, Sanchez, Jose Garcia, Curioni-Fontecedro, Alessandra, Gautschi, Oliver, Price, Gillian, Coate, Linda, von Moos, Roger, Zielinski, Christoph, Provencio, Mariano, Menis, Jessica, Ruepp, Barbara, Pochesci, Alessia, Roschitzki-Voser, Heidi, Besse, Benjamin, Rabaglio, Manuela, O’Brien, Mary E.R., Stahel, Rolf A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone metastases Carcinoma, Non-Small-Cell Lung - drug therapy Denosumab Denosumab - therapeutic use Female Humans Lung Neoplasms - drug therapy Male NSCLC RANK RANKL Reference Standards Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!